Kymera Therapeutics KYMR 深 沪
已收盘 09-19 16:00:00 美东时间
49.13
-2.030
-3.97%
华盛通- 最 高51.50
- 今 开51.26
- 成交量 255.58万股
- 最 低 48.71
- 昨 收 51.16
- 总市值 35.13亿
- 52周最高 53.23
- 市盈率 静 --
- 换手率 3.57%
- 52周最低 19.445
- 委 比 -89.30%
- 总股本 7149.76万
- 历史最高 91.92
- 量 比 2.66
- 振 幅 5.45%
- 历史最低 9.60
- 每 手 1
- 风险率 9.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses
Kymera Therapeutics announced positive Phase 1 results for KT-621, an oral STAT6 degrader, showing rapid STAT6 degradation in blood and skin, Th2 biomarker reductions, and a safety profile similar to placebo. KT-621’s data highlight its potential to mimic dupilumab-like activity while offering once-daily oral convenience. The company plans to report Phase 1b AD trial results and initiate Phase 2b studies in AD and asthma in 4Q25 and 1Q26, respect...
09-17 11:00
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
RBC Capital Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $70
RBC Capital analyst Brian Abrahams initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $70.
09-16 21:02
Kymera Therapeutics Announces New Chief Legal Officer
Kymera Therapeutics ( ($KYMR) ) has issued an announcement. On September 3, 202...
09-03 19:28
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
Kymera Therapeutics宣布Brian Adams被任命为首席法律官和公司秘书，接替即将退休的Ellen Chiniara。Adams拥有近二十年的法律和生命科学经验，将领导公司的法律、治理和知识产权事务。Kymera致力于开发口服小分子降解剂药物，用于治疗免疫疾病。Adams的加入将进一步推动公司创新药物的临床开发和商业化进程。
09-03 11:00
Kymera Therapeutics Q2 EPS $(0.95) Misses $(0.84) Estimate, Sales $11.476M Miss $21.214M Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.84) by 12.83 percent. This is a 63.79 percent decrease over losses of $(0.58) per share
08-11 19:04
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Kymera Therapeutics reported positive results for KT-621, an oral STAT6 degrader, with Phase 1 healthy volunteer data exceeding expectations. The Phase 1b trial in moderate to severe atopic dermatitis (AD) is on track to report data by year-end 2025, with Phase 2b trials in AD and asthma expected to begin next. The company also advanced KT-579, an oral IRF5 degrader, with IND-enabling studies ongoing. Additionally, Kymera entered a strategic part...
08-11 11:00
